Clinical validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: results from a prospective multi-center clinical study.
Infectious vaginitis due to bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginalis accounts for a significant proportion of all gynecologic visits in the United States. A prospective multicenter clinical study was conducted to validate the performance of two new in vitro diagnostic transcription-mediated amplification nucleic acid amplification tests (NAAT) for diagnosis of BV, VVC, and trichomoniasis. Patient- and clinician-collected vaginal swab samples obtained from women with symptoms of vaginitis were tested with the Aptima BV and Aptima CV/TV assays. Results were compared to Nugent score (plus Amsel for intermediate Nugent) for BV, Candida cultures and DNA sequencing for VVC, and a composite of a NAAT and culture for T. vaginalis The prevalence of infection was similar for clinician- and patient-collected samples: 49% for BV, 29% for VVC due to Candida species group, 4% for VVC due to C. glabrata, and 10% for T. vaginalis Sensitivity and specificity estimates for the investigational tests in clinician-collected samples were, respectively, 95.0% and 89.6% for BV, 91.7% and 85.8% for Candida species group, 84.7% and 99.1% for C. glabrata, and 96.5% and 98.9% for T. vaginalis Sensitivity and specificity were similar in patient-collected samples. In a secondary analysis, clinician's diagnosis, in-clinic assessments, and investigational assay results were compared to gold standard reference methods. Overall, the investigational assays had higher sensitivity and specificity than clinician's diagnoses and in-clinic assessments, indicating the investigational assays were more predictive of infection than traditional diagnostic methods. These results provide clinical efficacy evidence for two IVD NAATs that can detect the main causes of vaginitis.